rna
interfer
rnai
control
gene
silenc
live
organ
potenti
clinic
applic
rnai
repres
strategi
unsurpass
select
abil
target
multipl
diseaserel
gene
independ
perceiv
drugabl
design
highli
select
efficaci
small
interf
sirna
short
hairpin
rna
shrna
becom
routin
owe
signific
progress
model
chemistri
rnai
significantli
downregul
gene
express
function
vitro
vivo
includ
brain
essay
highlight
recent
find
pharmaceut
industri
intend
appli
rnai
treatment
neuropsychiatr
diseas
rnai
rna
interfer
cellular
surveil
mechan
repress
viral
infect
transpos
element
repetit
gene
eg
transgen
also
regul
gene
express
well
normal
cell
develop
refer
rnai
although
posttranscript
gene
silenc
ptg
anoth
close
way
describ
becom
almost
embarrass
explain
rnai
past
year
rnai
subject
numer
review
meet
even
public
rnai
scientif
breakthrough
year
scienc
magazin
fortun
magazin
label
rnai
biotech
billion
dollar
breakthrough
whole
issu
natur
magazin
dedic
rnai
rnai
concept
even
found
new
york
time
list
bestsel
last
least
rnai
grant
nobel
prize
medicin
physiolog
year
first
public
reminisc
hype
experienc
oligonucleotid
antisens
technolog
led
numer
public
review
meet
creation
biotech
lead
field
similar
one
read
today
websit
sever
compani
special
rnai
nevertheless
numer
attempt
valid
target
preclin
use
rnai
first
attempt
treat
disord
resist
small
molecular
entiti
approach
close
alreadi
clinic
essay
primarili
deal
rnai
context
cn
disord
although
clear
rout
success
long
one
case
effect
gene
silenc
rna
interfer
depend
natur
andor
structur
sirna
shrna
mrna
sequenc
target
gene
sirna
design
becom
effici
although
method
use
vari
wide
cell
penetr
stabil
remain
key
factor
variou
approach
taken
seen
good
penetr
stabil
use
nake
sirna
well
modifi
one
vitro
vivo
investig
experiment
genomewid
sirna
librari
high
throughput
sirna
screen
greatli
increas
abil
design
valid
potent
sirna
especi
combin
use
predict
algorithm
guid
artifici
neural
network
current
common
gener
sirna
singl
target
produc
close
downregul
mrna
least
vitro
success
rate
vivo
level
downregul
vari
markedli
depend
rnai
target
tissu
dose
durat
rout
administr
far
pronounc
long
last
knock
rather
except
rule
state
introduct
see
box
earli
concern
rnai
relat
nonspecif
offtarget
gene
activ
induct
innat
immun
system
interferon
respons
although
seem
littl
relev
appli
sirna
exampl
nt
long
anoth
issu
relat
endogen
small
regulatori
rna
known
microrna
mirna
multitud
may
exist
may
involv
regul
embryon
develop
cell
fate
determin
unknown
function
inhibit
mirna
exampl
link
cancer
gener
use
high
dose
sirnashrna
may
satur
risc
complex
lead
profoundli
toxic
even
lethal
effect
shown
recent
shrna
direct
hepat
b
viru
howev
model
sirna
toxic
effect
rna
interfer
formul
biovail
pharmacokinet
metabol
one
major
challeng
overcom
creat
effect
sirna
compound
deliveri
stabil
vitro
vivo
foreign
dsrna
cell
recogn
viral
pathogen
rapidli
elimin
requir
rather
high
dose
schedul
sirna
shrna
protein
liposom
conjug
system
chemic
modifi
protect
sirna
show
better
stabil
longer
elimin
half
live
nake
sirna
shield
f
ome
h
stabil
sirna
special
liposom
compound
show
higher
potenc
longer
durat
action
use
lower
dose
potenti
avoid
oligonucleotiderel
side
effect
coupl
nake
sirna
carrier
molecul
variou
type
help
target
activ
sirna
site
need
reduc
amount
sirna
intak
necessari
therapeut
effect
anoth
improv
target
deliveri
principl
sirna
modifi
cyclodextrin
polymerbas
nucleic
acid
approach
nanoparticl
technolog
polym
system
contain
transferrin
taken
cancer
cell
overexpress
transferrin
receptor
current
approach
appli
antibodi
exampl
local
inject
andor
perfus
strategi
discret
compart
exampl
within
eye
spine
appear
best
suit
sirna
drug
deliveri
futur
deliveri
modal
may
adapt
patient
andor
diseas
implant
minipump
connect
deep
brain
deliveri
devic
contrari
notic
nake
slightli
modifi
sirna
quit
stabl
exampl
week
cerebrospin
fluid
minipump
implant
mice
week
wealth
vitro
rnai
public
vivo
data
comparison
spars
howev
last
year
much
convinc
evid
publish
show
rnai
applic
inde
result
downregul
mrna
level
produc
select
potent
function
rnai
evolutionarilyconserv
plant
planaria
hydra
trypanosom
drosophila
mammal
posttranscript
genesilenc
ptg
event
trigger
cytoplasm
long
doublestrand
ds
rna
cleav
rnase
iii
enzym
dicer
gener
short
interf
si
rna
sirna
nucleotid
nt
long
dsrna
contain
phosphoryl
end
overhang
strand
sirna
get
incorpor
multiprotein
rnainduc
silenc
complex
risc
unwind
sirna
duplex
sirna
strand
retain
risc
guid
entir
complex
target
mrna
depend
complimentar
target
mrna
sequenc
sirna
guid
strand
risc
initi
either
endonucleolyt
cleavag
translat
arrest
target
mrna
furthermor
risc
may
facilit
format
heterochromatin
rnai
induc
gene
silenc
even
transcript
level
rnai
regul
endogen
gene
express
via
similar
mechan
howev
use
singlestrand
rna
imperfectli
selfcomplementari
sequenc
fold
back
form
hairpin
rna
hairpin
rna
provid
sourc
dsrna
cleav
dicer
gener
singlestrand
micro
mi
rna
mirna
like
sirna
guid
strand
steer
protein
complex
target
endogen
mrna
initi
rnaimedi
silenc
endogen
gene
rnai
offer
rapid
effici
mean
somat
gene
knock
potent
convent
antisens
oligodeoxynucleotid
ribozym
approach
importantli
mimic
pharmacolog
target
valid
partial
inhibit
target
gene
function
thu
rnai
increasingli
use
sinc
discoveri
gener
dsrnamedi
lossoffunct
phenotyp
deciph
function
novel
gene
dsrna
longer
nt
effect
downregul
gene
express
invertebr
includ
aplysia
planaria
drosophila
howev
mammalian
cell
dsrna
induc
toxic
interferon
respons
lead
cell
death
follow
global
mrna
translat
arrest
result
protein
kinas
rmediat
phosphoryl
translat
initi
factor
nonspecif
mrna
degrad
oligoadenyl
synthasernas
l
mark
contrast
long
dsrna
sirna
induc
interferon
respons
although
produc
sequencespecif
gene
knockdown
mammalian
cell
effect
knockdown
exogen
well
endogen
gene
demonstr
sever
mammalian
organ
liver
lung
spleen
kidney
pancrea
skelet
muscl
even
brain
use
intravascular
inject
nasal
instil
local
injectionsperfus
addit
rnai
use
multitud
studi
explor
pathophysiolog
potenti
therapeut
applic
anim
model
cancer
viral
infect
autoimmun
inflammatori
neurolog
psychiatr
diseas
obvious
latter
case
rout
applic
key
hurdl
one
reli
icv
repeat
local
inject
effect
rang
differ
sphere
differ
anim
speci
thu
local
administr
sirna
intranas
intrathec
intravitr
rout
show
protect
model
lung
ischemia
neuropath
pain
neovascular
eye
intraven
administr
sirna
apolipoprotein
b
apob
reduc
apob
mrna
protein
level
total
cholesterol
mice
stabl
sirna
given
iv
rout
result
long
last
knockdown
hepat
b
viru
hbv
replic
mice
numer
report
success
viral
deliveri
shrna
brain
howev
discuss
approach
space
constraint
surprisingli
exogen
appli
sirna
success
use
silenc
gene
function
mous
brain
spite
perceiv
limit
cn
approach
see
box
thu
direct
perfus
egfpsirna
mgday
week
third
ventricl
egfp
transgen
mice
knock
egfp
mrna
protein
level
effect
pronounc
week
treatment
compar
one
week
region
select
although
rel
extens
distribut
throughout
brain
clearli
lesser
effect
structur
distant
inject
site
eg
olfactori
bulb
pon
cerebellum
minim
affect
interestingli
good
relationship
egfp
mrna
protein
knock
week
data
provid
good
case
pursu
approach
similarli
sirna
mous
dopamin
dat
serotonin
transport
sert
specif
downregul
respect
mrna
protein
sirna
produc
behavior
effect
name
hyperlocomotor
activ
antidepressantrel
behavior
respect
parallel
pharmacolog
blockad
dat
sert
function
produc
potent
dat
inhibitor
gbr
select
inhibitor
serotonin
uptak
ssri
paroxetin
interestingli
although
downregul
mrna
protein
rather
limit
sirna
treatment
produc
full
blown
behavior
effect
compar
observ
follow
maxim
effect
pharmacolog
intervent
dat
inhibitor
ssri
full
ko
observ
transgen
mice
along
line
salahpour
et
al
use
sirna
dat
day
tyrosin
hydroxylas
th
day
inject
ventral
tegmentalsubstantia
nigra
area
brain
adult
wild
type
datknockout
mice
respect
sirna
result
reduct
dat
th
protein
level
striatum
respect
dat
knockdown
littl
effect
noveltyinduc
locomot
locomotor
respons
dat
sirna
treat
anim
amphetamin
blunt
similar
observ
dat
heterozygot
anim
th
sirna
experi
carri
datknockout
anim
show
increas
depend
newli
synthes
dopamin
knockdown
th
anim
result
reduc
basal
locomot
wang
et
al
use
sirna
direct
huntingtin
gene
repress
transgen
mutant
huntingtin
express
huntington
diseas
mous
model
singl
intraventricular
inject
sirna
mg
lipofectamin
postnat
day
knock
transgen
huntingtin
express
induc
decreas
number
size
intranuclear
inclus
striatal
neuron
week
sirna
treatment
significantli
prolong
mice
longev
week
improv
motor
function
slow
loss
bodi
weight
data
becam
even
intrigu
receptor
target
sirna
limit
mrna
knock
observ
two
differ
sirna
yet
behavior
effect
mark
pronounc
observ
receptor
knock
mous
result
clearli
suggest
partial
target
mrna
protein
downregul
produc
mark
function
effect
parallel
obtain
best
avail
pharmacolog
treatment
gener
applic
point
becom
interest
inde
although
sirna
shrna
appear
efficaci
vitro
target
knock
efficaci
close
situat
vivo
look
far
much
less
promis
sever
investig
report
vivo
rnaiinduc
knock
variou
target
limit
thu
keep
mind
limit
cn
target
drug
deliveri
number
possibl
target
primarili
neurolog
disord
rather
extens
see
tabl
especi
target
strong
genet
compon
resist
classic
pharmaceut
approach
shrna
normal
deliv
viral
approach
howev
zhang
et
al
use
origin
strategi
develop
express
plasmid
encod
shrna
direct
human
egfr
mrna
shrna
encapsul
pegyl
immunoliposom
target
brain
cancer
human
glioma
receptorspecif
monoclon
antibodi
mab
murin
mab
human
insulin
receptor
rat
mab
mous
transferrin
nonvir
gene
transfer
technolog
deliv
liposomeencapsul
plasmid
dna
across
cellular
barrier
receptorspecif
target
ligand
first
clearli
shrna
approach
highli
promis
larg
major
initi
work
establish
rnai
carri
vitro
rodent
nonhuman
primat
rnai
make
progress
intranas
sirna
sar
coronaviru
scv
shown
treat
sar
rhesu
macaqu
model
cynomolgu
monkey
singl
iv
specif
sirna
apolipoprotein
b
apob
encapsul
stabl
nucleic
acid
lipid
particl
snalp
produc
dosedepend
silenc
apob
mrna
express
liver
h
administr
maxim
silenc
signific
reduct
apob
protein
serum
cholesterol
lowdens
lipoprotein
level
observ
h
treatment
last
day
highest
sirna
dose
demonstr
immedi
potent
last
biolog
effect
sirna
treatment
thu
clinic
relev
rnaimedi
gene
silenc
concomit
function
effect
rodent
nonhuman
primat
support
rnai
viabl
therapeut
principl
biotech
pharmaceut
compani
often
partnership
deal
plan
alreadi
perform
clinic
trial
base
sirna
therapeut
principl
see
tabl
number
potenti
diseas
target
use
rna
interfer
sirna
shrna
use
viral
approach
regular
dsrna
almost
unlimit
especi
diseas
escap
classic
pharmaceut
treatment
complex
viral
autoimmun
neurolog
metabol
oncolog
andor
genet
diseas
quick
look
portfolio
exampl
isi
alnylam
illustr
breadth
rnai
target
diseas
current
work
vascular
endotheli
growth
factor
vegf
agerel
macular
degener
amd
diabet
retinopathi
diabet
macular
edema
allergan
target
genet
gsk
vegf
amd
huntington
diseas
respiratori
diseas
copd
transplant
reject
autoimmun
diseas
transmembran
conduct
regul
cftr
cystic
fibrosi
respiratori
syncyti
viru
rsv
upper
airway
infect
phase
ii
nogo
protein
spinal
cord
injuri
influenza
viru
pandem
flu
protein
tyrosin
phosphatas
type
diabet
posit
phase
ii
mirna
lower
cholesterol
triglycerid
diabet
apolipoprotein
homozyg
famili
hypercholesterolemia
orphan
drug
statu
phase
ii
cuzn
superoxyd
amyotroph
later
sclerosi
cellular
adhes
molecul
ulcer
coliti
irrit
bowel
diseas
crohn
diseas
phase
iii
interleukin
receptor
asthma
rhiniti
creactiv
protein
crp
coronari
heart
diseas
glucagon
receptor
diabet
late
multipl
sclerosi
phase
ii
clusterin
prostat
cancer
solid
tumor
exampl
nonsmal
cell
lung
cancer
breast
cancer
phase
ii
insulinlik
growth
factor
receptor
psoriasi
phase
survivin
eukaryot
initi
factor
e
variou
cancer
phase
heat
shock
protein
variou
cancer
craf
kinas
agerel
macular
degener
diabet
retinopathi
thu
clinic
trial
alreadi
way
target
diseas
instanc
amd
certain
virus
exampl
hepat
b
c
hiv
rsv
papilloma
viru
clear
cn
disord
first
line
treatment
prioriti
neurologicneurodegen
disord
consid
serious
larg
fact
genom
neurodegen
disord
much
advanc
psychiatr
disord
result
phase
phase
ii
studi
made
avail
scientif
meet
andor
press
confer
releas
recent
august
sirna
therapeut
announc
first
posit
result
clinic
trial
patient
wet
form
amd
road
target
like
parkinson
alzheim
huntington
prion
diseas
deliveri
repres
real
challeng
place
see
box
compani
like
alnylam
enter
partnership
medtron
appli
sirna
directli
brain
deep
brain
deliveri
devic
latter
diseas
ideal
suit
rnai
treatment
affect
mutat
protein
wherea
normal
form
remain
unaffect
possibl
rnai
exquisit
select
one
target
protein
variant
form
wherea
parent
protein
remain
principl
untouch
even
suggest
rnai
may
work
specif
certain
snp
singl
nucleotid
polymorph
preliminari
report
meet
obvious
remain
confirm
vivo
claim
need
confirm
final
remain
seen
whether
treatment
interfer
natur
risc
pathway
given
high
dose
need
produc
full
blown
knock
gene
express
rna
interfer
potenti
target
entir
genom
protein
soon
drugabl
sirna
limit
cytoplasm
target
wherea
shrna
reach
nucleu
chemic
design
sirna
becom
almost
flawless
least
vitro
high
knockdown
specif
potenc
regularli
achiev
main
issu
still
remain
share
featur
potenti
drug
bioavail
deliveri
resist
metabol
tissu
brain
penetr
elimin
toxicolog
sever
recent
paper
show
sirna
downregul
gene
express
protein
function
vivo
specif
function
outcom
includ
blood
variou
organ
peripher
central
nervou
system
clinic
trial
run
least
plan
big
pharma
biotech
far
limit
success
immunotoxin
gene
therapi
antisens
agent
ribozym
great
hope
rnai
therapeut
emerg
support
numer
pre
clinic
find
report
last
year
hope
better
knowledg
diseas
mechan
certainli
advanc
say
year
antisens
era
start
combin
signific
expertis
sirnadesign
deliveri
meet
success
especi
numer
aspect
bioscienc
genet
chemistri
genom
bioinformat
model
formul
significantli
progress
howev
common
clinic
trial
due
everincreas
demand
public
regulatori
author
one
pragmat
expect
success
mani
failur
wherea
viral
approach
look
promis
anim
expect
rout
taken
clinic
situat
extrem
great
care
repeat
tragedi
occur
gene
therapi
field
thu
one
see
stepwis
approach
use
sirna
probabl
target
intract
diseas
virus
infecti
agent
local
set
eye
common
diseas
target
right
balanc
found
gene
silenc
possibl
side
effect
interferon
respons
satur
risc
complex
thu
target
effect
possibl
one
soon
abl
modul
express
endogen
rnai
system
name
microrna
area
inde
promis
like
drug
like
candid
chemic
protein
immun
radiochem
therapeut
window
dictat
feasibl
approach
eventu
success
come
care
design
studi
target
well
valid
access
treatment
pharmacokinet
metabol
aspect
well
control
major
toxicolog
alert
new
technolog
advanc
success
failur
especi
earli
trial
conduct
biotech
common
mani
trial
stop
unexpect
side
effect
lack
efficaci
safeti
issu
poor
bioavailabilti
metabol
lack
brain
penetr
pragmat
cash
run
rememb
antisens
therapi
gene
therapi
spite
great
promis
encount
difficulti
beyond
capac
biotech
launch
candid
treatment
today
still
antisens
treatment
approv
doubt
rna
interfer
repres
major
therapeut
advanc
approach
come
time
human
genom
function
link
target
diseas
becom
better
known
importantli
regulatori
author
societi
industri
prepar
move
toward
person
medicin
smaller
target
popul
better
genet
biomark
better
link
diseas
ultim
greater
chanc
success
cure
entir
patient
popul
littl
therapeut
hope
particularli
true
neurodegen
disord
genet
caus
psychiatr
disord
better
establish
rnai
may
repres
primari
strategi
target
valid
possibl
therapi
least
drug
treatment
resist
popul
clear
anim
neuropsychiatr
disord
model
rnai
produc
mark
behavior
effect
least
pronounc
establish
pharmacolog
treatment
complet
gene
knock
